You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mesylate Apatinib

Showing 1 - 25 of 860
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Apatinib Mesylate
  • Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
  • Changsha, Hunan, China
    Xiangya Hospital, Central South University
Mar 1, 2023

Esophageal Cancer by AJCC V8 Stage Trial in Zhengzhou (Camrelizumab+Apatinib+Chemotherapy?Camrelizumab+Apatinib,

Recruiting
  • Esophageal Cancer by AJCC V8 Stage
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 12, 2023

Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Nov 6, 2022

Solid Tumor Trial in Henan (Camrelizumab combined with apatinib mesylate)

Recruiting
  • Solid Tumor
  • Camrelizumab combined with apatinib mesylate
  • Henan, China
    Henan Tumor Hospital
May 15, 2022

Cholangiocarcinoma Trial (Carrilizumab, Albumin-bound paclitaxel, Apatinib)

Not yet recruiting
  • Cholangiocarcinoma
  • (no location specified)
Dec 9, 2022

Gastric Cancer Trial in Seoul (Apatinib mesylate)

Completed
  • Gastric Cancer
  • Apatinib mesylate
  • Seoul, Songpa-gu, Korea, Republic of
    Asan medical center
Jul 20, 2022

Camrelizumab Combined With Apatinib Mesylate in Unresectable

Recruiting
  • Hepatocellular Carcinoma
    • Fuzhou, Fujian, China
      Mengchao Hepatobiliary Hospital, Fujian Medical University
    Aug 24, 2022

    Immunotherapy, Gastrict Cancer Trial in Fuzhou (Tislelizumab, Apatinib Mesylate, oxaliplatin)

    Recruiting
    • Immunotherapy
    • Gastrict Cancer
    • Fuzhou, China
      Fujian cancer hospital
    Jan 17, 2023

    Gastric Cancer Trial in Beijing (Apatinib, Oxaliplatin, S1)

    Recruiting
    • Gastric Cancer
    • Beijing, Beijing, China
      Beijing Cancer Hospital / Peking University Cancer Hospital
    Jan 30, 2023

    Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)

    Not yet recruiting
    • Locally Advanced Biliary Tract Cancer
    • Metastatic Biliary Tract Cancer
    • Camrelizumab and Apatinib Plus GP
    • Guangzhou, Guangdong, China
      Cancer center of SunYat-sen University
    Feb 15, 2023

    Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

    Active, not recruiting
    • Metastatic Castration Resistant Prostate Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Sep 23, 2022

    Hepatocellular Carcinoma Trial in Hangzhou (Apatinib Mesylate, Camrelizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Hangzhou, Zhejiang, China
      the First Affiliated Hospital, School of Medicine, Zhejiang Univ
    Jan 16, 2022

    Sarcoma Trial in Shanghai (MASCT-I,PD1 Antibody,Apatinib)

    Active, not recruiting
    • Sarcoma
    • MASCT-I,PD1 Antibody,Apatinib
    • Shanghai, Shanghai, China
      Shanghai Sixth People's Hospital
    Nov 22, 2022

    Hepatocellular Carcinoma Trial in Jinan (Camrelizumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Jinan, Shandong, China
      Shandong Cancer Hospital and Institute
    Nov 16, 2022

    Hepatocellular Carcinoma Trial (TACE+Camrelizumab+Apatinib mesylate, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • TACE+Camrelizumab+Apatinib mesylate
    • TACE
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Oct 17, 2022

    Gastrointestinal Cancer, Immunotherapy, Targeted Therapy Trial in Harbin (Camrelizumab, Apatinib Mesylate)

    Recruiting
    • Gastrointestinal Cancer
    • +2 more
    • Harbin, Heilongjiang, China
      Harbin Medical University
    Feb 4, 2022

    Soft Tissue Sarcoma Trial in Guangzhou (Apatinib Mesylate, doxorubicin, ifosfamide)

    Recruiting
    • Soft Tissue Sarcoma
    • Apatinib Mesylate, doxorubicin, ifosfamide
    • Guangzhou, China
      Sun Yat-sen University Cancer Center
    Nov 15, 2021

    Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Apatinib Mesylate Tablets, Tegafur Gimeracil Oteracil Potassium

    Completed
    • Head and Neck Squamous Cell Carcinoma
    • Apatinib Mesylate Tablets
    • Tegafur Gimeracil Oteracil Potassium Capsules
    • Shanghai, Shanghai, China
      Shanghai ninth people's hospital
    Jul 20, 2022

    Esophageal Tumors Trial (Apatinib, The chemotherapeutic drug chosen by the investigator.)

    Withdrawn
    • Esophageal Neoplasms
    • Apatinib
    • The chemotherapeutic drug chosen by the investigator.
    • (no location specified)
    Apr 11, 2022

    Healthy Subjects Trial in Beijing (Apatinib Mesylate)

    Completed
    • Healthy Subjects
    • Apatinib Mesylate
    • Beijing, Beijing, China
      Beijing Luhe Hospital, Capital Medical University
    Oct 19, 2021

    Head and Neck Squamous Cell Carcinoma Trial (Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin)

    Not yet recruiting
    • Head and Neck Squamous Cell Carcinoma
    • Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin
    • (no location specified)
    Dec 29, 2021

    Sarcoma,Soft Tissue, Extremity, Trunk Trial in Beijing (Apatinib Mesylate)

    Recruiting
    • Sarcoma,Soft Tissue
    • +5 more
    • Apatinib Mesylate
    • Beijing, Beijing, China
      Radiotherapy Department of Cancer Hospital, Chinese Academy of M
    Feb 8, 2022

    Cancer Trial in Santa Monica (Apatinib, Nivolumab)

    Active, not recruiting
    • Cancer
    • Santa Monica, California
      Sarcoma Oncology Research Center
    May 19, 2022

    Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (Camrelizumab,

    Not yet recruiting
    • Metastatic Gastric Adenocarcinoma
    • Metastatic Gastroesophageal Junction Adenocarcinoma
    • Guangzhou, Guangdong, China
      The Sixth Affiliated hosipital, Sun Yat-Sen University
    Apr 16, 2022

    Locally Advanced NSCLC Trial in Beijing (Camrelizumab, PD-1 mAb, Apatinib, VEGFR2 antibody)

    Recruiting
    • Locally Advanced Non-Small Cell Lung Cancer
    • Camrelizumab, PD-1 monoclonal antibody
    • Apatinib, VEGFR2 antibody
    • Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Aug 15, 2022